Adaptimmune Therapeutics PLC (ADAPY): Cash & Equivalents
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$91.14M
As of 2024-12-31
$26.06M
As of 2025-06-30
-15.3%
3-year compound annual growth
+12.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $91.14M | -36.7% | 2025-03-24, Balance as of period end |
| 2023-12-31 | $143.99M | +33.3% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $108.03M | -28.0% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $149.95M | +163.6% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $56.88M | +12.8% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $50.41M | -26.3% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $68.38M | -18.6% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $84.04M | -47.1% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $158.78M | -18.3% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $194.26M | n/a | 2017-03-13, Balance as of period end |
| 2015-06-30 | $229.05M | n/a | 2017-03-13, Balance as of period end |